HK1209341A1 - Treatment of motor and movement disorder side effects associated with parkinsons disease treatments - Google Patents

Treatment of motor and movement disorder side effects associated with parkinsons disease treatments

Info

Publication number
HK1209341A1
HK1209341A1 HK15110110.7A HK15110110A HK1209341A1 HK 1209341 A1 HK1209341 A1 HK 1209341A1 HK 15110110 A HK15110110 A HK 15110110A HK 1209341 A1 HK1209341 A1 HK 1209341A1
Authority
HK
Hong Kong
Prior art keywords
treatment
motor
side effects
effects associated
movement disorder
Prior art date
Application number
HK15110110.7A
Other languages
English (en)
Chinese (zh)
Inventor
Emer Leahy
Bavani Shankar
Original Assignee
Psychogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psychogenics Inc filed Critical Psychogenics Inc
Publication of HK1209341A1 publication Critical patent/HK1209341A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15110110.7A 2012-06-11 2015-10-15 Treatment of motor and movement disorder side effects associated with parkinsons disease treatments HK1209341A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261658401P 2012-06-11 2012-06-11
PCT/US2013/044509 WO2013188210A2 (en) 2012-06-11 2013-06-06 Treatment of motor and movement disorder side effects associated with parkinson's disease treatments

Publications (1)

Publication Number Publication Date
HK1209341A1 true HK1209341A1 (en) 2016-04-01

Family

ID=49715794

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110110.7A HK1209341A1 (en) 2012-06-11 2015-10-15 Treatment of motor and movement disorder side effects associated with parkinsons disease treatments

Country Status (16)

Country Link
US (2) US20130331399A1 (ar)
EP (1) EP2858649B1 (ar)
JP (3) JP2015523989A (ar)
KR (1) KR20150017763A (ar)
CN (1) CN105407879A (ar)
AU (1) AU2013274667B2 (ar)
BR (1) BR112014030813A2 (ar)
CA (1) CA2876203A1 (ar)
ES (1) ES2765200T3 (ar)
HK (1) HK1209341A1 (ar)
IL (1) IL236107A0 (ar)
MX (1) MX2014015266A (ar)
NZ (1) NZ702730A (ar)
RU (1) RU2014150942A (ar)
SG (1) SG11201408240TA (ar)
WO (1) WO2013188210A2 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
CN109438352A (zh) 2008-10-28 2019-03-08 艾尼纳制药公司 治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
CN109562085A (zh) 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
KR101749675B1 (ko) * 2015-07-20 2017-06-26 동국대학교 산학협력단 멜라닌 응집 호르몬을 유효성분으로 포함하는 파킨슨병 치료 및 레보도파 부작용 억제용 약학 조성물
WO2019040527A1 (en) * 2017-08-21 2019-02-28 The Board Of Trustees Of The Leland Stanford Junior University DOPA FORMULATIONS FOR TREATMENTS OF PARKINSON'S DISEASE
WO2020110128A1 (en) * 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
CN112955134A (zh) * 2018-07-19 2021-06-11 英倍尔药业股份有限公司 用于治疗帕金森氏病的左旋多巴和多巴脱羧酶抑制剂的呼吸道递送

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US7706871B2 (en) * 2003-05-06 2010-04-27 Nellcor Puritan Bennett Llc System and method of prediction of response to neurological treatment using the electroencephalogram
ES2675544T3 (es) * 2008-05-30 2018-07-11 Psychogenics Inc. Tratamiento para trastornos mentales y neurológicos
EP2317996A1 (en) * 2008-06-24 2011-05-11 Anders Björklund Eltoprazine for suppression of l-dopa induced dyskinesias
DE102008030539B4 (de) * 2008-06-27 2016-05-12 BSH Bosch und Siemens Hausgeräte GmbH Haushaltsgerät
JP5597198B2 (ja) * 2008-07-14 2014-10-01 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 超音波を使用して細胞活動を調節するための方法およびデバイス
TW201029995A (en) * 2008-12-05 2010-08-16 Merz Pharma Gmbh & Co Kgaa Use of eltoprazine for the treatment of L-DOPA-induced dyskinesia
RU2611376C2 (ru) * 2010-10-15 2017-02-21 Контера Фарма Апс Фармацевтическая композиция для лечения, профилактики или облегчения двигательных расстройств и ее применение

Also Published As

Publication number Publication date
JP2018083842A (ja) 2018-05-31
US20130331399A1 (en) 2013-12-12
JP2015523989A (ja) 2015-08-20
CN105407879A (zh) 2016-03-16
EP2858649B1 (en) 2019-10-23
WO2013188210A2 (en) 2013-12-19
RU2014150942A (ru) 2016-07-27
EP2858649A2 (en) 2015-04-15
NZ702730A (en) 2017-08-25
KR20150017763A (ko) 2015-02-17
EP2858649A4 (en) 2016-05-25
AU2013274667A1 (en) 2015-01-22
US20180250295A1 (en) 2018-09-06
IL236107A0 (en) 2015-01-29
SG11201408240TA (en) 2015-01-29
JP2020073549A (ja) 2020-05-14
ES2765200T3 (es) 2020-06-08
MX2014015266A (es) 2015-06-23
CA2876203A1 (en) 2013-12-19
WO2013188210A3 (en) 2015-07-02
BR112014030813A2 (pt) 2018-05-15
AU2013274667B2 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
HK1209341A1 (en) Treatment of motor and movement disorder side effects associated with parkinsons disease treatments
HK1203977A1 (en) Enhancement of transport of therapeutic molecules across the blood brain barrier
EP2819703A4 (en) TREATMENT OF PAIN
PL2908758T3 (pl) Lektromagnetyczne urządzenie do zabiegów na skórze
EP2906208A4 (en) THERAPEUTIC TREATMENT
HK1225962A1 (zh) 使用溶瘤腺病毒的腦癌治療
SG11201500685PA (en) Warm-cool beauty treatment device
EP2863949A4 (en) METHOD FOR THE TREATMENT OR PREVENTION OF PARODONTITIS AND DISORDERS ASSOCIATED WITH PARODONTITIS
EP2872120A4 (en) TARGETED THERAPEUTIC NANOPARTICLES
GB201506561D0 (en) Treatment of amblyopia
IL237460B (en) Treatment of post-traumatic stress disorder with an isolated microbacterium
EP2802302A4 (en) APPLYING ENERGY FOR MEDICAL TREATMENTS
HK1207004A1 (en) Treatment of mild and moderated alzheimers disease
EP2861244A4 (en) TREATMENT OF SLEEP APNEA
GB2497886B (en) Hair treatment methods
EP3010524A4 (en) Protamine in treatment of neuronal injuries
HK1207984A1 (en) Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
GB2500999B (en) Hair treatment methods
GB201214456D0 (en) Therapeutic treatments
GB201214454D0 (en) Therapeutic treatments
GB201222544D0 (en) Photodynamic therapy and diagnosis
GB201208502D0 (en) Treatment of digestive disorder 2
GB201204645D0 (en) Treatment of disease
GB201208505D0 (en) Treatment of skin condition
GB201208048D0 (en) Treatment of digestive disorder